The introduction of novel therapeutic agents for advanced prostate cancer has led to a wide
range of treatment options for patients with metastatic castration-resistant prostate cancer …

Circulating tumor DNA (ctDNA) enables real-time genomic profiling of cancer without the
need for tissue biopsy. ctDNA-based technology is seeing rapid uptake in clinical practice …

No consensus strategies exist for prognosticating metastatic castration-resistant prostate
cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by …

De novo metastatic prostate cancer is highly aggressive, but the paucity of routinely
collected tissue has hindered genomic stratification and precision oncology. Here, we …

Purpose: Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have
sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may …

Purpose: Androgen receptor pathway inhibitors (ARPI) are standard of care for treatment-
naïve metastatic castration-resistant prostate cancer (mCRPC), but rapid resistance is …

Background Multiple treatments are available for metastatic castration-resistant prostate
cancer (mCRPC), including androgen receptor signaling inhibitors (ARSI) enzalutamide and …

Background and objective Recently, research on treatment intensification has gathered
momentum, and three novel therapy combinations were approved for metastatic castration …

Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA
released into the bloodstream primarily from cancer cells undergoing apoptosis. In …

In the present investigation, we engineered some 1, 2, 3-triazole clubbed and dichloro
substituted novel aurones as potential anticancer agents well capable of targeting digestive …